title: Prophylactic laparoscopic ovarian ablation for premenopausal breast cancer: medical and economic efficacy.
abstract: Worldwide analysis showed a highly significant reduction in the annual rates both of recurrence and of death produced by ovarian ablation. We examined the safety, efficacy, and cost-effectiveness of prophylactic laparoscopic oophorectomy for premenopausal breast cancer. Prophylactic laparoscopic oophorectomy was attempted in 15 selected premenopausal patients with breast cancer. After mastectomy, these patients had laparoscopic ovarian ablation as treatment for breast carcinoma with positive estrogen receptors. To evaluate the economic impact of laparoscopic oophorectomy, comparisons were made between patients treated laparoscopically and those treated with conventional surgery, chemotherapy, and hormonal therapy. The average time required for laparoscopic bilateral oophorectomy was 44 min. Oral intake was resumed the next morning, and the patients were discharged 3 days after surgery. No limitation on physical activity and no complications were required during postoperative days. There was no reduction in the overall costs of laparoscopic surgery and conventional surgery in Japan. The cost of one year's supply of tamoxifen was equivalent to the overall cost of surgical oophorectomy. From medical and economic viewpoints, we conclude that laparoscopic ovarian ablation should be considered an alternative to adjuvant chemotherapy in premenopausal women.
authors.affiliation: First Department of Surgery, Kansai Medical University, Osaka, Japan.
authors.forename: A H
authors.initials: AH
authors.lastname: Kwon
authors.forename: O
authors.initials: O
authors.lastname: Yamada
authors.forename: S
authors.initials: S
authors.lastname: Uetsuji
authors.forename: Y
authors.initials: Y
authors.lastname: Matsui
authors.forename: Y
authors.initials: Y
authors.lastname: Kamiyama
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000191:economics / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant / Q000191:economics; D003362:Cost-Benefit Analysis; D004032:Diet; D016527:Drug Costs; D004965:Estrogen Antagonists / Q000191:economics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010535:Laparoscopy / Q000191:economics / Q000379:methods; D007902:Length of Stay; D015410:Mastectomy, Extended Radical; D015413:Mastectomy, Simple; D008875:Middle Aged; D010052:Ovariectomy / Q000191:economics / Q000379:methods*; D010351:Patient Discharge; D017697:Premenopause; D011960:Receptors, Estrogen / Q000032:analysis; D012449:Safety; D013629:Tamoxifen / Q000191:economics / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D013629:Tamoxifen